<DOC>
	<DOCNO>NCT00686790</DOCNO>
	<brief_summary>The objective study determine effectiveness peginterferon alfa-2b 1.5 mcg/kg/week administer 52 week ( wk ) previously untreated participant coinfected hepatitis virus B D. After 52-week treatment 52-week follow-up , virologic , biochemical , histological response evaluate .</brief_summary>
	<brief_title>Efficacy Peginterferon Alfa-2b Previously Untreated Subjects With Chronic Hepatitis B D Co-infection ( Study P04603 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Hepatitis D</mesh_term>
	<mesh_term>Hepatitis D , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Participants must demonstrate willingness participate study comply procedure sign write informed consent . Age 1865 year old . HBsAg positive &gt; 6 month . ALT &gt; = 2 ULN &gt; 6 month . HDV RNA positive serology . Serum antibody hepatitis delta antigen IgG IgM class . Knodell score HAI &gt; = 6 F &gt; = 0 ; positive test intrahepatic Delta antigen liver biopsy . Women childbearing potential ( include woman less 1 year postmenopausal woman become sexually active ) must use acceptable method birth control ( e.g. , hormonal contraceptive , medically prescribe IUD , condom combination spermicide ) surgically sterilize ( e.g. , hysterectomy tubal ligation ) . Participants must free clinically significant disease ( chronic hepatitis B D ) , would interfere study evaluation . Participants must understand able adhere dose visit schedule , agree record symptom severity score , medication time , concomitant medication , adverse event accurately consistently daily diary . Age &lt; 18 &gt; 65 . Concomitant HCV and/or HIV infection . Actual liver failure ( total serum bilirubin &gt; 2.5 x normal , prolonged prothrombin time &gt; 3 sec , serum albumin &lt; 3 g/dl , history ascites , variceal bleeding , hepatic encephalopathy ) . Toxic autoimmune hepatitis ( ANA titer &gt; 1:160 ) , metabolic liver disease ( Wilson disease , hemochromatosis , Î±1 antitrypsin deficiency ) Women pregnant nursing . Leukopenia ( &lt; 2500/mm^3 ) , neutropenia ( &lt; 1000/mm^3 ) , hemoglobin &lt; 10 g/dl , presence severe disease ( myocardiopathy , diabetes mellitus , arterial hypertension , neoplasia , neurologic disease , malnutrition ) . Antiviral , immunomodulatory , corticosteroid , chemotherapeutical treatment within 6 month participation study . Depression and/or psychiatric disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis D</keyword>
	<keyword>Hepatitis B</keyword>
</DOC>